Sensitive and specific immunodetection of human glandular kallikrein 2 in serum

Clinical Chemistry

Volumn 46, Issue 2, 2000, Pages 198-206

  Becker, Charlotte ^a   Piironen, Timo ^b   Kiviniemi, Johanna ^b   Lilja, Hans ^a   Pettersson, Kim ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE KALLIKREIN;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CROSS REACTION; FLUOROMETRY; HUMAN; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DETERMINATION;

ANIMALIA;

EID: 0033968433     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.2.198     Document Type: Article

References (50)

1. 1. Schedlich LJ, Bennetts B, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987:6:429-37.
2. 2. Chapdelaine P, Paradis G, Tremblay RR, Dubé JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988;236:205-8.
3. 3. Henttu P, Lukkarinen O, Vihko P. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 1990;45: 654-60.
4. 4. Young C-F, Andrews PE, Montgomery BT, Tindall DJ. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 1992;31:818-24.
5. 5. Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
6. 6. Ahlgren G, Rannevik G, Lilja H. Impaired secretory function of the prostate in men with oligo-asthenozoospermia. J Androl 1995;16: 491-8.
7. 7. Deperthes D, Chapdelaine P, Tremblay RR, Brunei C, Berton J, Hébert J, et al. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1995; 1245:311-6.
8. 8. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994;78:1536-9.
9. 9. Diamandis EP, Yu H, Sutherland JA. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:301-10.
10. 10. Hsieh ML, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, et al. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res 1997;57:2651-6.
11. 11. Clements JA, Mukhtar A, Verity K, Pullar M, McNeill P, Cummins J, et al. Kallikrein gene expression in human pituitary tissues. Clin Endocrinol 1996;44:223-31.
12. 12. Lövgren J, Valtonen-André C, Marsal K, Lilja H, Lundwall A. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 1999;20:348-55.
13. 13. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Investig 1985;76: 1899-903.
14. 14. Lövgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997;238:549-55.
15. 15. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. J Biol Chem 1997;272: 21582-8.
16. 16. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi M. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-4.
17. 17. Deperthes D, Frenette G, Brillard-Bourdet M, Bourgeois L, Gauthier F, Tremblay RR, et al. Potential involvement of kallikrein hK2 in the hydrolysis of human seminal vesicle proteins after ejaculation. J Androl 1996;17:659-65.
18. 2+ and extracellular protease inhibitors. Eur J Biochem 1999;262: 781-9.
19. 19. Frenette G, Tremblay RR, Lazure C, Dubé JY. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 1997; 71:897-9.
20. 20. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
21. 21. Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
22. 22. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen M-T, Cockett ATK, et al. Serum prostate-specific antigen complexed to α-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
23. 23. Darson MF, Pacelli A, Roche P, Rittenhouse PF, Wolfert RL, Young CYF, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
24. 24. Saedi MS, Cass MMJ, Goel AS, Grauer L, Hogen KL, Okaneya T, et al. Overexpression of a human prostate-specific glandular kallikrein, hk2, in E. coli and generation of antibodies. Mol Cell Endocrinol 1995;109:237-41.
25. 25. Lövgren J, Piironen T, Övermo C, Dowell B, Karp M, Pettersson K, et al. Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 1995;213:888-95.
26. 26. Kumar A, Goel AS, Hill TM, Mikolajczyk SD, Millar LS, Kuus-Reichel K, et al. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res 1996:5397-402.
27. 27. Eerola R, Piironen T, Pettersson K, Lövgren J, Vehniainen M, Lilja H, et al. Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate specific antigen. Prostate 1997;31:84-90.
28. 28. Frenette G, Deperthes D, Tremblay RR, Lazure C, Dubé JY. Purification of enzymatically active kallikrein hk2 from human seminal plasma. Biochim Biophys Acta 1997;1334:109-15.
29. 2-Macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Blood Cells Mol Dis 1998;24:412-9.
30. 30. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Prostatic human glandular kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer 1999;81:438-42.
31. 31. Piironen T, Lövgren J, Karp M, Eerola R, Lundwall A, Dowell B, et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein 2 (hK2)in serum. Clin Chem 1996;42:1034-41.
32. 32. Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4-10 ng/mL. Urology 1998;52:360-5.
33. 33. Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lummen G, Wernli M, et al. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 1998;83:2540-7.
34. 34. Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (hK2) in serum. J Urol 2000;in press.
35. 35. Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem 1999;45:790-9.
36. 36. Klee GG, Goodmanson MK, Jacobsen SJ, Young CYF, Finlay JA, Rittenhouse HG, et al. Highly sensitive automated chemilumino-metric assay for measuring free human glandular kallikrein-2. Clin Chem 1999;45:800-6.
37. 37. Rajakoski K, Piironen T, Pettersson K, Lövgren J, Karp M. Epitope mapping of human prostate specific antigen and glandular kallikreins expressed in insect cells. Prostate Cancer Prostatic Dis 1997;1:16-20.
38. 1antichymotrypsin. Clin Chem 1991;37:618-25.
39. 39. Lövgren T, Hemmilä I, Pettersson K, Eskola JU, Bertoff E. Determination of hormones by time-resolved fluoroimmunoassay. Talanta 1984;31:909-16.
40. 40. Matikainen MT, Terho P. Immunochemical analysis of antigenic determinants of Chlamydia trachomatis by monoclonal antibodies. J Gen Microbiol 1983;129:2343-50.
41. 41. Fazekas de St Groth S, Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J Immunol Methods 1980;35:1-21.
42. 42. Staszewski R. Cloning by limiting dilution: an improved estimate that an interesting culture is monoclonal. Yale J Biol Med 1984; 57:865-8.
43. 43. Piironen T, Villoutreix B, Becker C, Hollingsworth K, Vihinen M, Bridon D, et al. Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Sci 1998;7:259-69.
44. 44. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 1949;51:660-72.
45. 1-antichymotrypsin complex. Clin Chem 1995;41: 1480-8.
46. 46. Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-20.
47. 47. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson P-A, et al. Free, complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154: 1090-5.
48. 48. Spencer CA, Takeuchi M, Kazarosyan M, MacKenzie F, Beckett GJ, Wilkinson E. Interlaboratory/intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurements of subnormal concentrations of TSH. Clin Chem 1995;41:367-74.
49. 49. Finlay JA, Evans CL, Day JR, Payne JK, Mikolajczyk SD, Millar LS, et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998;51:804-9.
50. 50. Grauer LS, Finlay JA, Mikolajczyk SD, Pusateri KD, Wolfert RL Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl 1998;19:407-11.